The point emphasized in our study, as the first clinical trial that investigated the effect of spironolactone as an MR antagonist on the cognitive deficits of patients with bipolar disorder in manic episodes, is the effectiveness of this medication in improving the cognitive deficits of these patients after 8 weeks in comparison with the control group. Here, NR3C2 is linked to bipolar disorder.